MLN0128 A Phase Ib Study of the Combination of MLN0128 (Dual TORC I/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Triple-Negative Breast Cancer (TNBC)
This Study is
No Longer Enrolling
Details
Age
Adult
Phase
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Type of Study
Treatment
Scope
Local
Locations
University of Colorado Hospital
Study ID
Protocol Number: 15-1135
More information available at ClinicalTrials.gov: NCT02719691
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers